Inhibition by levamisole of the organic cation transporter rOCT1 in cultured rat hepatocytes

Pharmacological Research

Volumn 40, Issue 3, 1999, Pages 275-279

  Martel, F ^a   Ribeiro, L ^a   Calhau, C ^a   Azevedo, I ^a  

^a Inst of Pharmacol and Therapeutics   (Portugal)

Author keywords

Hepatocytes; Levamisole; MPP+; rOCT1; Transport

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CARRIER PROTEIN; CATION; LEVAMISOLE; ORGANIC CATION TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BILIARY EXCRETION; CATION TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG UPTAKE; ISOTOPE LABELING; LIVER CELL CULTURE; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032832230     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1999.0506     Document Type: Article

References (38)

1. Klaassen CD, Watkins III J. Mechanisms of bile formation, hepatic uptake, and biliary excretion. Pharmacol Rev 1984; 36: 1-67.
2. Meijer D, Mol W, Muller M, Kurz G. Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations. J Pharmacokinet Biopharm 1990; 18: 35-70.
3. Oude Elferink RPJ, Meijer DKF, Kuipers F, Jansen PLM, Groen AK, Groothuis GMM. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim Biophys Acta 1995; 1241: 215-68.
4. Zhang L, Brett CM, Giacomini KM. Role of organic cation transporters in drug absorption and elimination. Ann Rev Pharmacol Toxicol 1998; 38: 431-60.
5. Martel F, Vetter T, Russ H, Gründemann D, Azevedo I, Koepsell H, Schömig E. Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 354: 320-6.
6. 2 and rOCT1: effects of catecholamines, metanephrines and corticosterone. Naunyn-Schmiedeberg's Arch Pharmacol, in press.
7. Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994; 372: 549-52.
8. + in cultured rat hepatocytes. Br J Pharmacol, in press.
9. Williams JC. Anthelmintic treatment strategies: current status and future. Vet Parasitol 1997; 72: 461-70.
10. Martin RJ, Robertson AP, Bjorn H. Target sites of anthelmintics. Parasitology 1997; 114(Suppl): S111-24.
11. Martin RJ, Murray I, Robertson AP, Bjorn H, Sangster N. Anthelmintics and ion-channels: after a puncture, use a patch. Int J Parasitol 1998; 28: 849-62.
12. Chirigos MA. Immunomodulators: current and future development and application. Thymus 1992; 19(Suppl 1): S7-20.
13. Hadden JW. T-cell adjuvants. Int J Immunopharmacol 1994; 16: 703-10.
14. Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 1991; 9: 2052-66.
15. Amery WK, Bruynseels JP. Levamisole, the story and the lessons. Int J Immunopharmacol 1992; 14: 481-6.
16. Casillas S, Pelley RJ, Milsom JW. Adjuvant therapy for colorectal cancer: present and future perspectives. Dis Colon Rectum 1997; 40: 977-92.
17. Conley BA, Kaplan RS, Arbuck SG. National Cancer institute clinical trials program in colorectal cancer. Cancer Chemother Pharmacol 1998; 42(Suppl): S75-9.
18. 3H]-levamisole in rats. J Pharm Pharmacol 1982; 34: 310-13.
19. 3H]levamisole in the rat after oral and intramuscular administration. Xenobiotica 1983; 13: 407-13.
20. 3H]levamisole in pigs after oral and intramuscular administration. Am J Vet Res 1983; 44: 583-7.
21. Kouassi E, Caille G, Lery L, Lariviere L, Vezina M. Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. Biopharm Drug Dispos 1986; 7: 71-89.
22. Mombarg M, Claessen H, Lambrechts L, Zwart P. Quantification of percutaneous absorption of metronidazole and levamisole in the fire-bellied toad (Bombina orientalis). J Vet Pharmacol Ther 1992; 15: 433-6.
23. 14C-levamisole in the lactating cow. Xenobiotica 1996; 26: 863-75.
24. Bradford M. A rapid method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
25. Sayre LM. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett 1989; 48: 121-49.
26. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16: 871-81.
27. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM (1997) Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51: 913-21.
28. Hohage H, Lelleck S, Stachon A, Haxelmans S, Koepsell H, Schlatter E. Activation by forskolin of the organic cation transporter rOCT1 expressed in HEK293 cells. Naunyn-Schmiedeberg's Arch Pharmacol 1998; (Suppl): R741.
29. 1 cells. Fluorometric studies with 4-(4-dimethylaminostyryl)-N-methylpyridinium. J Pharmacol Exp Ther 1998; 286: 305-10.
30. Chan AW-L, Kellen JA. Resistance to levamisole (R12456) in heat-stable alkaline phosphatases. Clin Chim Acta 1975; 60: 91-6.
31. Chan JR, Stinson RA. Dephosphorylation of phosphoproteins of human liver plasma membranes by endogenous and purified liver alkaline phosphatases. J Biol Chem 1986; 261: 7635-9.
32. Montessuit C, Caverzasio J, Bonjour JP. Characterization of a Pi transport system in cartilage matrix vesicles. Potential role in the calcification process. J Biol Chem 1991; 266: 17791-7.
33. Sarrouilhe D, Lalegerie P, Baudry M. Endogenous phosphorylation and dephosphorylation of rat liver plasma membrane proteins, suggesting a 18 kDa phosphoprotein as a potential substrate for alkaline phosphatase. Biochim Biophys Acta 1992; 1118: 116-22.
34. Sarrouilhe D, Metaye T, Rivet G, Lalegerie P, Baudry M. Stabilization of phospho-intermediates of rat liver plasma membrane alkaline phosphatase by uncompetitive inhibition. Relation with phosphate uptake into hepatocytes. Cell Mol Biol 1993; 39: 469-77.
35. Becq F, Jensen TJ, Chang XB, Savoia A, Rommens JM, Tsui LC, Buchwald M, Riordan JR, Hanrahan JW. Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc Natl Acad Sci USA 1994; 91: 9160-4.
36. Vanhoutte PM, Van Neuten JM, Verbeuren TJ, Laduron PM. Differential effects of the isomers of tetramisole on adrenergic neurotransmission in cutaneous veins of the dog. J Pharmacol Exp Ther 1977; 200: 127-40.
37. Pires JGP, Futuro-Neto HA, Oliveira AM, Cabral AM. The effect of levamisole on the cardiac responses to sympathomimetics and on the amine uptake process. J Pharm Pharmacol 1979; 31: 257-8.
38. Graefe K-H, Bönisch H. The transport of amines across the axonal membrane of noradrenergic and dopaminegic neurones. In: (Trendelenburg U, Weiner N, eds) Catecholamines I. Hand Exp Pharmacol vol. 90/I. Berlin: Springer-Verlag, 1988: 193-245.